Australien - Englisch - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Israel - Englisch - Ministry of Health

a.l. medi-market ltd. - nitroprusside sodium anhydrous - powder for solution for infusion - nitroprusside sodium anhydrous 52.75 mg - nitroprusside - nipruss is indicated in:• hypertensive crisis• controlled intraoperative hypotension nipruss is not suitable for permanent therapy.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

medsurge pharma limited - sodium nitroprusside dihydrate 25 mg/ml - concentrate for injection - 50 mg/2ml - active: sodium nitroprusside dihydrate 25 mg/ml excipient: water for injection - indicated for: - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Kanada - Englisch - Health Canada

pfizer canada ulc - sodium nitroprusside - solution - 25mg - sodium nitroprusside 25mg - direct vasodilators

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

northstar rx llc - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules, usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase produci

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 100 mg in 5 ml - cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of escherichia coli and proteus mirabilis . cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of haemophilus influenzae , moraxella catarrhalis , and streptococcus pyogenes . (efficacy for streptococcus pyogenes in this organ system was studied in fewer than 10 infections.) note: for patients with otitis media caused by streptococcus pneumoniae , overall response was approximately 10% lower for cefixime than for the comparator [see clinical studies (14)] . cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isolates of

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

redpharm drug, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents: community-acquired pneumonia: caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhali

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

atlantic biologicals corps - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxe

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lupin limited - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see cli